US imposes 100% tariff on imported patented pharmaceuticals, impacting Australian exporters like CSL
Consensus Summary
Donald Trump imposed a 100% tariff on patented pharmaceuticals manufactured outside the US on July 31, 2025, targeting Australia’s $1.3–2 billion annual drug exports, primarily from CSL. The move aims to re-shoring production to the US, offering reduced tariffs (20%) for companies relocating factories and zero tariffs for those securing ‘most favoured nation’ drug pricing deals. Australia’s largest exporter, CSL, has invested heavily in US manufacturing and may qualify for exemptions due to its existing facilities and plasma-derived therapies. The tariff excludes generic drugs and applies only to patented products, with exemptions for countries like Japan, the EU, and the UK that negotiated lower rates. The Australian government, led by Health Minister Mark Butler, has firmly rejected pressure to alter the country’s subsidized Pharmaceutical Benefits Scheme (PBS), calling it ‘world leading’ and non-negotiable. Opposition Leader Angus Taylor pledged to work with the government to overturn or exempt Australian exporters. The tariff is legally distinct from Trump’s earlier ‘Liberation Day’ tariffs, which were struck down by the US Supreme Court in February 2025, as it is enacted under Section 232 of the Trade Expansion Act for national security reasons. Critics argue the tariff could disrupt global pharmaceutical supply chains and increase costs for US consumers, while supporters claim it will boost domestic manufacturing and address pricing disparities with other countries.
✓ Verified by 2+ sources
Key details reported by multiple sources:
- Donald Trump signed an executive order imposing a 100% tariff on patented pharmaceuticals manufactured outside the US on July 31, 2025 (ABC, SMH, THEAGE, NEWSCOMAU, GUARDIAN).
- Australia exported approximately $1.32–$2 billion worth of pharmaceuticals to the US in 2024–2025 (NEWSCOMAU, ABC, GUARDIAN).
- CSL (ASX-listed biotech firm) is Australia’s largest pharmaceutical exporter to the US, with manufacturing plants in the US, Australia, and Europe (SMH, THEAGE, NEWSCOMAU, GUARDIAN).
- CSL announced a $1.5–$2.2 billion expansion of its US manufacturing facility in Kankakee, Illinois, set to complete by 2031 (SMH, NEWSCOMAU, GUARDIAN).
- The tariff applies to patented drugs only, excluding generic medicines (NEWSCOMAU, ABC).
- Companies moving production to the US can reduce tariffs to 20% (SMH, THEAGE, ABC, GUARDIAN).
- Australia has a long-standing free trade agreement with the US, but no specific pharmaceutical tariff carve-out (SMH, THEAGE, NEWSCOMAU).
- The tariff is enacted under Section 232 of the Trade Expansion Act, not presidential emergency powers, making it unaffected by the Supreme Court’s February 2025 ruling (SMH, ABC, NEWSCOMAU).
- Japan, EU, South Korea, Switzerland, and Liechtenstein received 10–15% tariff rates, while the UK secured a 10% rate (SMH, THEAGE, NEWSCOMAU, GUARDIAN).
- Australia’s Pharmaceutical Benefits Scheme (PBS) subsidizes drug prices, which the US administration has criticized as undermining ‘most favoured nation’ pricing principles (SMH, THEAGE, NEWSCOMAU, GUARDIAN).
- Health Minister Mark Butler stated Australia would not negotiate changes to the PBS, calling it ‘world leading’ (SMH, THEAGE, NEWSCOMAU, GUARDIAN, SBS).
- Large pharmaceutical companies have 120 days to announce re-shoring plans or face tariffs, while smaller firms have 180 days (SMH, THEAGE, ABC, GUARDIAN).
- CSL’s plasma-derived therapies (majority of its US exports) may qualify for exemptions if they meet urgent US health needs (SMH, THEAGE, NEWSCOMAU).
- Opposition Leader Angus Taylor said the Coalition would work with the government to overturn or exempt Australian exporters from tariffs (SMH, THEAGE, GUARDIAN).
Points of Difference
Details reported by only one source:
- A White House official explicitly stated ‘Australia does not have a special pharma tariff rate’ (noted in SMH only).
- The executive order text mentions ‘plasma derived therapies’ would be exempt if from countries with a trade deal or meeting urgent US health needs (SMH specifies ‘certain circumstances’).
- The 100% tariff is described as the ‘highest possible rate’ with ‘carve-outs for other countries’ (SMH phrasing).
- The article notes Trump’s executive order was timed to mark one year since his ‘Liberation Day’ tariffs (February 2025) (SMH only).
- The SMH article mentions adjustments to steel tariffs (50% to 0–25% based on steel content) as part of the broader executive order.
- The article repeats SMH’s content almost verbatim with no additional details.
- Specifies Australia exported $US1.32bn of pharmaceuticals to the US in 2025 (not $1.91bn as in ABC), citing UN COMTRADE data (NEWSCOMAU only).
- Includes a direct quote from Prime Minister Marles (not mentioned in other sources) about Australia’s 20-year free trade agreement with the US.
- Highlights that Medicines Australia warned of ‘significant scrutiny’ over new medicine launches in Australia due to US ‘most favoured nation’ rules (NEWSCOMAU only).
- States the tariff applies to ‘major companies including AstraZeneca, Johnson & Johnson, and Pfizer’ (NEWSCOMAU only).
- Notes that AstraZeneca and others have already struck deals with the White House under ‘most favoured nation’ pricing (NEWSCOMAU only).
- Communications Minister Anika Wells is quoted saying the PBS is ‘not for sale’ and ‘world leading’ (GUARDIAN only).
- The Guardian specifies Trump’s tariff is part of broader efforts to force manufacturers to ‘agree to drug-pricing deals or commit to making their products domestically’ (GUARDIAN phrasing).
- The Guardian notes that American consumers pay ‘far more for prescription medicines than Australians’ as a key motivation for the tariff (GUARDIAN only).
- The Guardian mentions affordability is a ‘key issue in the November midterm congressional elections’ (GUARDIAN only).
- A senior administration official is quoted saying ‘too many drugs that were driven by research and development here in America are now produced abroad’ (ABC phrasing).
- The ABC notes Trump previously said the tariff could be as high as 200% (ABC only).
- The ABC specifies CSL’s social media post in September 2024 suggested the tariff would take effect from October 2024 (ABC only).
- The ABC mentions the US argues domestic pharmaceutical production is necessary for ‘global conflict or emergencies like a pandemic’ (ABC only).
- The ABC states the tariff is being implemented under ‘national security’ powers (ABC phrasing).
- SBS only includes a brief headline and Health Minister Butler’s quote calling the decision ‘deeply disappointing and deeply concerning’ (no additional details).
Contradictions
Conflicting information between sources:
- NEWSCOMAU reports Australia exported $US1.32bn in pharmaceuticals to the US in 2025, while ABC and GUARDIAN report $US1.3–2bn (ABC uses 2024 data).
- SMH and THEAGE do not mention the ‘most favoured nation’ deals struck by AstraZeneca, Johnson & Johnson, and Pfizer, which NEWSCOMAU explicitly states were already negotiated.
- ABC states Trump previously said the tariff could be as high as 200%, but this detail is not mentioned in SMH, THEAGE, or NEWSCOMAU.
- NEWSCOMAU claims the tariff applies to ‘major companies including AstraZeneca, Johnson & Johnson, and Pfizer,’ while SMH and THEAGE focus on CSL and do not name these companies.
- GUARDIAN emphasizes Trump’s tariff is part of a broader push to force ‘drug-pricing deals,’ but SMH and THEAGE frame it primarily as a ‘re-shoring’ measure.
Source Articles
Australia says it won’t raise drug prices after Trump’s 100% tariff on pharmaceuticals imported into US
Health minister Mark Butler says federal government is ‘not negotiating’ when it comes to removing price protections on common medications Get our breaking news email , free app or daily news podcast ...
Breaking: Trump puts 100pc tariff on some pharmaceuticals
The US president's latest order shows he remains committed to his aggressive tariff regime despite February's Supreme Court ruling that invalidated his centrepiece "liberation day" tariffs....
What Trump's 100 per cent pharmaceutical tariff means for Australia
Australia exported nearly two billion dollars worth of pharmaceuticals to the US last year....
Trump slaps huge tariff on medicines
US President Donald Trump has followed through on another tariff threat, putting a 100 per cent levy on a major Australian export....
Trump imposes 100 per cent tariff on Australian drugs – but with caveats
Australia’s largest biotech firm, CSL, could be exempt from the new tariffs, which will not apply to therapies derived from blood plasma in certain circumstances....
Trump imposes 100 per cent tariff on Australian drugs – but with caveats
Australia’s largest biotech firm, CSL, could be exempt from the new tariffs, which will not apply to therapies derived from blood plasma in certain circumstances....